JAMA · 1980 · 150 citations · 13 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyLipid BiochemistryCardiovascular DiseaseHypertension ManagementHypertension PharmacotherapyLipid DisordersLipid-lowering TherapyLipoprotein AnalysisHigh-density Lipoprotein MetabolismLipid Profile ChangesLipid Profile EffectsLow-density Lipoprotein Cholesterol LoweringLow-density Lipoprotein Cholesterol ReductionPlacebo ComparatorsSubjectsTriglyceride Lowering
In a joint Veterans Administration-National Heart, Lung, and Blood Institute study of mild hypertension, 1,012 men and women, 21 to 50 years of age and with diastolic pressure from 85 to 105 mm Hg, were randomized into two double-blind treatment groups. Subjects in the active group received chlorthalidone or chlorthalidone plus reserpine, while the other subjects received matching placebo tablets. After one year of treatment, the chlorthalidone group had increases of 10.0 +/- 1.8 (SE) mg/dL in total cholesterol level, 9.8 +/- 5.2 mg/dL in triglyceride level, and 12.6 +/- 3.4 mg/dL in low-density lipoprotein-cholesterol level above the changes in the placebo group. There was no difference in high-density lipoprotein changes between the two groups (0.1 +/- 0.8 mg/dL). The possible net effect on risk of increasing lipid values while lowering pressure in the long-term treatment of mild hypertension with thiazides or related diuretics must be further evaluated.
13
Enzymatic Determination of Total Serum Cholesterol
Charles C. Allain, Lucy S Poon, Cicely S G Chan et al. · Clinical Chemistry · 1974 · 9.2K citations · Full text